Facts
- HQ
- United States
- Sectors
- Venture capital, Finance
- Founded
- 1977
TwelveLabs Secures $100M Series B Led by NEA and Naver Ventures to Expand Video AI Platform
TwelveLabs raised $100 million in a Series B round to expand its enterprise video AI platform, which helps organizations analyze and monetize large video archives through natural language processing. The funding round was co-led by NEA and Naver Ventures, reflecting a trend of increased investment in specialized vertical AI solutions.
TechCrunch names first five VC judges for Startup Battlefield 200 at Disrupt 2025; $100,000 prize on Oct. 27–29 in San Francisco
TechCrunch announced the first five venture capitalists who will judge Startup Battlefield 200 at Disrupt 2025 (Oct. 27–29, San Francisco), where 20 finalists will compete for a $100,000 equity-free prize. The event spotlights alumni like Dropbox and Cloudflare and invites attendees to register for tickets and watch founders pitch to top investors.
Seattle Biotech Tune Therapeutics Raises $175M to Advance Epigenetic Editing Trials for Chronic Hepatitis B
Seattle-based biotech startup Tune Therapeutics raised $175 million to support clinical trials of its epigenetic editing treatments for chronic Hepatitis B. The funding will aid development of therapies that control gene expression without altering DNA, leveraging technology developed at Duke University.
Tune Therapeutics launches with $40M to commercialize TEMPO epigenomic platform for tuning gene activity
Tune Therapeutics, a biotech based in Seattle and Durham, N.C., launched with $40 million to develop TEMPO, an epigenomic platform that locates and fine-tunes gene activity to treat rare single-gene disorders and more common conditions. The leadership includes co‑founders Charles Gersbach, Akira Matsuno, and Fyodor Urnov and several veterans of Seattle cell therapy companies.
Shape Therapeutics raises $112M to advance RNA-editing platform and AAV gene-delivery for neurological and genetic diseases
Seattle preclinical biotech Shape Therapeutics raised $112 million to develop RNA-editing and gene therapy technologies, including improved AAV delivery vectors and an RNA editing platform. The company, led by CEO and co-founder Francois Vigneault and leveraging work from co-founder Prashant Mali, aims to target neurological and genetic diseases such as Parkinson's, Alzheimer’s, alpha-1 antitrypsin deficiency, and Rett syndrome.
Frazier Healthcare Partners launches $100M SPAC, Frazier Lifescience Acquisition Corporation (FLAC), to pursue biotech deals
Seattle venture firm Frazier Healthcare Partners filed with the SEC to raise $100 million for a SPAC called Frazier Lifescience Acquisition Corporation (FLAC) led by four Frazier executives, aiming to target biotechnology companies to develop therapies and generate investor returns.
NEA leads $37.5M Series B in Seattle cloud startup Pulumi, bringing total funding to $57.5M
Seattle startup Pulumi raised $37.5 million in a Series B led by NEA, bringing its total funding to $57.5 million to expand R&D and sales/marketing. NEA partner Aaron Jacobson will join Pulumi’s board alongside existing investors Madrona Venture Group and Tola Capital.
